ArticleParasitology research2025
Identifying zoonotic risks: molecular insights into Cryptosporidium and Enterocytozoon bieneusi in pediatric cancer patients in Ahvaz, 2024.
Article in Parasitology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Parasite in cancer therapy: molecular mechanisms and translational potential.Frontiers in immunology · 2026Review
- Molecular Characterization and Zoonotic Potential ofTransboundary and emerging diseases · 2026Article
- Distribution of human-pathogenicFrontiers in microbiology · 2025Article
- PCR-based detection ofFrontiers in cellular and infection microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Opportunistic infections remain a major cause of morbidity and mortality among patients with immunodeficiency and malignancy. Cryptosporidium spp. and microsporidia, particularly Enterocytozoon bieneusi, are obligate intracellular parasites that can lead to severe complications and even death in immunocompromised individuals.In this cross-sectional study, 60 stool samples were collected from pediatric oncology patients aged 5-18 years who were hospitalized at Baghaei 2 Hospital in Ahvaz, southwestern Iran, in 2024. Following DNA extraction, molecular analysis was performed to detect the presence of Cryptosporidium spp. and E. bieneusi. For genotyping, amplification and sequencing of the 60-kDa glycoprotein (gp60) gene for Cryptosporidium spp. and the internal transcribed spacer (ITS) region for E. bieneusi were conducted. A total of 16 samples (26.6%) tested positive for either C. hominis or E. bieneusi. Co-infection with both pathogens was identified in two patients (3%). Statistical analysis revealed no significant association between gender and parasitic infection (P = 0.166), nor between the type of malignancy and presence of protozoa (P = 0.717). Genotyping of E. bieneusi showed the presence of BEB6, CHG3, D, and I genotypes, with BEB6 being the most prevalent. Subtyping of C. hominis revealed the presence of the IeA11G3T3 subtype. Overall, the molecular findings demonstrated a prevalence rate 26.6 % of parasitic infection among the studied population, with E. bieneusi being predominant. The detection of potentially zoonotic genotypes, particularly BEB6, underscores the likelihood of zoonotic transmission routes in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.